Board of Directors

Cora M. Tellez


Cora Tellez joined the CorMedix Board of Directors in April 2014 and was elected Chair of the Board in May 2014. Ms. Tellez serves as President and CEO of Sterling HSA, a company she founded in 2004. She has 25 years of management experience in healthcare finance and delivery. Prior to founding Sterling HSA, Ms. Tellez was President of the Health Plans division of Health Net, Inc., an insurance provider that operated in seven states and achieved revenue of $8 billion from health plans. She has also served as President of Prudential’s western healthcare operations, CEO of Blue Shield of California, Bay Region and Regional Manager for Kaiser Permenente of Hawaii. Ms. Tellez serves on the boards of HMS Holdings, Inc., (NASDAQ:HMSY) and Pacific Premier Bancorp, Inc., (NASDAQ;PPBI). She also serves on boards of several nonprofit organizations such as the Institute for Medical Quality.

Taunia Markvicka, Pharm D.


Taunia Markvicka joined the CorMedix Board of Directors in April 2014. Dr. Markvicka has a strong commercial and clinical background, and has extensive experience in managing a product strategy from development to commercialization, including market analysis, pre-launch planning, forecasts, budgets and launches. She is Senior Vice President, Chief Commercial Officer at Pacira Pharmaceuticals, prior to which she served as Pacira’s Vice President, Commercial. Dr. Markvicka is also a partner at Stack Pharmaceuticals, Inc., a commercialization, marketing, and strategy firm. Prior to Pacira, Dr. Markvicka served as a franchise marketing director at The Medicines Company for cardiovascular and hematology acute care products. Previously, Dr. Markvicka was Marketing Director at Watson Pharmaceuticals, where she oversaw marketing and new product planning for urology and general products.

Michael W. George


Michael George joined the CorMedix Board in February 2014. He is currently the Chief Executive Officer of Michael George & Associates, a healthcare -consulting firm. Prior to forming Michael George & Associates, Mr. George served as a restructuring and turnaround executive for aaiPharma Inc., Derm Tech International and Urocor, Inc. Prior to that, he served as President/North America of Elan Pharmaceuticals. He has more than 25 years of sales and marketing experience, including senior management positions, with three large pharmaceutical companies, DuPont Merck Pharmaceutical Company, Bristol Myers Pharmaceutical Company and Sandoz Pharmaceuticals, Inc. (now Novartis). Mr. George serves on the boards of ClearPath Diagnostics, Inc., a private company, and Coastal Horizons, Inc., a non-profit corporation. He holds a BS in Business Administration from Central Missouri State University (now the University of Central Missouri) and an MBA from New Hampshire College (now the University of Southern New Hampshire).

Myron Kaplan


Myron Kaplan joined the Board of CorMedix in May 2016. Mr. Kaplan is a founding partner of Kleinberg, Kaplan, Wolff & Cohen, P.C., where he has practiced corporate and securities law for more than forty years.  Among other responsibilities at the firm, Mr. Kaplan represents hedge funds and other companies in a broad spectrum of industries and works on financings, mergers and acquisitions, governance and compensation issues, distribution and license agreements and joint ventures. In 2012, Mr. Kaplan became a trustee of the Lehman Brothers Plan Holding Trust. He has served as a Director of a number of public companies and nonprofit organizations. Previously, he served as a member of the board of directors of SAirGroup Finance (USA) Inc., a subsidiary of SAirGroup that had publicly issued debt securities, Trans World Airlines, Inc. and Kitty Hawk, Inc. Mr. Kaplan graduated from Columbia College and holds a Juris Doctor from Harvard Law School.

Khoso Baluch

Director, Chief Executive Officer

Khoso Baluch was appointed Chief Executive Officer in October 2016. Mr. Baluch has built and led successful U.S. and international commercial teams in the primary care, specialty and hospital segments, launching leading products including Cialis, Byetta, Insulin devices, Cimzia, Vimpat and Neupro. During the 24 years Mr. Baluch worked for Eli Lilly & Co, he held international positions in general management, business development, market access and product leadership, and spanning Europe, the Middle East and the United States. At Lilly, as Diabetes Worldwide Franchise head, he had responsibility for guiding pipeline products from Phase 3 to completion on the market.  He oversaw a team of nearly 130 people responsible for the medical, regulatory, legal, supply chain, marketing, pricing and reimbursement aspects of drug launches in the U.S. and globally. Following his tenure at Lilly, Mr. Baluch held multiple positions at UCB, the global biopharmaceutical company, as Senior Vice President & Chief Marketing Officer and most recently serving as Senior Vice President & President European Middle East & Africa (EMEA) Region. Since 2013, Mr. Baluch has been a board member of Poxel, a French publically traded Biotech Company.

Janet D. Dillione


Janet Dillione joined the Board of CorMedix in August 2015. Since May of 2014 she has served as the Chief Executive Officer of Bernoulli Enterprise, Inc a real-time connected healthcare information technology company. Previously, she was Executive Vice President and General Manager of the Healthcare Division at Nuance Communications, Inc., a leading provider of voice and language solutions for businesses and consumers around the world. From June 2000 to April 2010, Ms. Dillione held several senior level management positions at Siemens Medical Solutions, a global leader in medical imaging, laboratory diagnostics, and healthcare information technology, including President and CEO of the global healthcare IT division. Ms. Dillione has more than 25 years of experience leading global teams in the development and delivery of healthcare technology and services. In that time, she has acquired both financial expertise and significant senior management experience as a chief operating officer and executive officer that will allow her to be a valued addition to the Company’s Board of Directors.